Mark Bodenrader
2021
In 2021, Mark Bodenrader earned a total compensation of $1.3M as Interim Chief Financial Officer, Vice President, Finance and Chief Accounting Officer at Cerevel Therapeutics Holdings.
Compensation breakdown
| Non-Equity Incentive Plan | $114,643 |
|---|---|
| Option Awards | $872,100 |
| Salary | $308,851 |
| Other | $17,400 |
| Total | $1,312,994 |
Bodenrader received $872.1K in option awards, accounting for 66% of the total pay in 2021.
Bodenrader also received $114.6K in non-equity incentive plan, $308.9K in salary and $17.4K in other compensation.
Rankings
In 2021, Mark Bodenrader's compensation ranked 7,782nd out of 12,415 executives tracked by ExecPay. In other words, Bodenrader earned more than 37.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,782 out of 12,415 | 37th |
Division Manufacturing | 3,435 out of 5,505 | 38th |
Major group Chemicals And Allied Products | 1,526 out of 2,375 | 36th |
Industry group Drugs | 1,357 out of 2,096 | 35th |
Industry Pharmaceutical Preparations | 1,001 out of 1,546 | 35th |
Source: SEC filing on April 28, 2022.
Bodenrader's colleagues
We found five more compensation records of executives who worked with Mark Bodenrader at Cerevel Therapeutics Holdings in 2021.
2021
N Coles
Cerevel Therapeutics Holdings
Chief Executive Officer
2021
Abraham Ceesay
Cerevel Therapeutics Holdings
President
2021
Kathy Yi
Cerevel Therapeutics Holdings
Chief Financial Officer
2021
Raymond Sanchez
Cerevel Therapeutics Holdings
Chief Medical Officer
2021
Scott Akamine
Cerevel Therapeutics Holdings